Advances in the management of alcohol-associated liver disease  

作　　者：Ahmad Anouti Thomas A.Kerr Mack C.Mitchell Thomas G.Cotter 

机构地区：[1]Division of Digestive and Liver Diseases,UT Southwestern Medical Center,Dallas,TX,USA

出　　处：《Gastroenterology Report》2024年第1期731-746,共16页胃肠病学报道(英文)

基　　金：T.G.C.is supported by the American Association for the Study of Liver Diseases(AASLD)Clinical,Translational and Outcomes Research Award(CTORA)and National Institute on Alcohol Abuse and Alcoholism(NIAAA)K23AA031310 grant;Research reported in this publication was supported by the NIAAA of the National Institutes of Health(NIH)under Award Number K23AA031310;The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.M.C.M.is supported by a grant from the National Institute on Alcohol Abuse and Alcoholism U01 AA026975;consults for GlaxoSmithKline,Amygdala NeProdigy,HepaTX,and Parvus;T.A.K.is supported by U01 AA026975 and has a research relationship with GSK and consults for Alexion.

摘　　要：Alcohol-associated liver disease(ALD)is a significant global health challenge,encompassing a spectrum from steatotic liver disease to cirrhosis and alcohol-associated hepatitis,and contributed to 25%of global cirrhosis deaths in 2019.The identification of both modifiable(e.g.heavy drinking,metabolic syndromes)and non-modifiable risk factors(e.g.genetic predispositions)is crucial for effective disease management.Alcohol use assessment and treatment,by using both behavioral therapy and pharmacotherapeutic modalities,nutrition support,and optimization of liver disease modifiers,form the cornerstone of management.Advances in medical therapies,such as fecal microbiota transplantation and novel agents such as IL-22,are being explored for their therapeutic potential.A unifying theme in ALD care is the need for a personalized approach to management,accounting for the spectrum of the disease and individual patient characteristics,to tailor interventions effectively.Finally,it is essential to address the challenges to effective ALD treatment,including socioeconomic,logistical,and stigma-related barriers,to improve patient outcomes.This review discusses the current knowledge on ALD,including epidemiology,pathophysiology,risk factors,and management strategies,highlighting the critical role of integrated care models.

关 键 词：alcohol-associated liver disease alcohol use disorder alcohol-associated hepatitis alcohol-associated cirrhosis steatotic liver disease 

分 类 号：R57[医药卫生—消化系统]